iShares Core Growth Allocation ETF vs Becton Dickinson and Co — how do they compare? iShares Core Growth Allocation ETF trades at $69.87, while Becton Dickinson and Co trades at $181.29 (market cap $48.93B). The key difference: Becton Dickinson and Co pays a 2.34% dividend while iShares Core Growth Allocation ETF pays none. Which is the better fit depends on your goals.
| AOR | BDX | |
|---|---|---|
52-Week High | $70.12 | $185.39 |
52-Week Low | $62.07 | $138.62 |
Market Cap | — | $48.93B |
Sector | — | Health |
Enterprise Value | — | $65.03B |
Dividend Yield | — | 2.34% |
Signals from Pluang's Aura AI — not financial advice
AOR, the iShares Core Growth Allocation ETF, trades at $70.12, up 0.57% on the day, with a bullish technical signal driven by moving averages. The ETF maintains a fixed 60/40 stock/bond allocation, rebalances semiannually, and offers low-cost exposure with a 0.20% fee. Recent news highlights its role as a core holding but notes long-term underperformance versus the S&P 500 over the past decade.
The outlook for AOR hinges on its diversified asset allocation strategy providing stability, though it faces risks from equity and fixed income market volatility. Its simplicity appeals to investors seeking a hands-off approach, but competition from pure equity funds and interest rate sensitivity are key considerations for potential returns.
BDX (Becton, Dickinson and Company) trades at $176.86, down 0.12% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q3 2026 revenue of $5.0 billion, up 4.4% FX-neutral, and raised full-year guidance, though margins faced pressure. Analyst sentiment is mixed with a consensus price target of $183.00, while institutional ownership remains stable amid positive news on GLP-1 therapy expansions and dividend declarations.
The stock offers steady growth potential with a 2.7% dividend yield and consistent earnings outperformance, but risks include margin compression, regulatory recalls, and high valuation multiples. Near-term resistance at $180 and support at $173 will test bullish momentum, with the current price near the consensus target suggesting limited upside without further catalysts.
Trailing returns across standard periods
Latest headlines on both assets
The fund is a fund of funds and seeks its investment objective by investing primarily in underlying funds that themselves seek investment results corresponding to their own respective underlying indexes. It generally will invest at least 80% of its assets in the component securities of its underlying index. The index measures the performance of the S&P Dow Jones Indices LLC proprietary allocation model.
Read more on AOR →Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →